Abstract:Although noticeable pathophysiological discrepancies exist in cancer and stroke, these two conditions share a common pathway, namely hypoxia‐associated angiogenesis. The possible mechanism behind this co‐occurrence has been pointed to the extracellular vesicle (EV)‐associated noncoding RNAs (ncRNAs). EV‐ncRNAs exhibit abilities to modulate angiogenesis both in the tumor microenvironment and in stroke. Moreover, EV delivery of ncRNA is expected to become an essential diagnostic, prognostic, and therapeutic tool. Ischemic stroke and systemic cancer are two of the leading causes of mortality. Hypoxia is a central pathophysiological component in ischemic stroke and cancer, representing a joint medical function. This function includes angiogenesis regulation. Vascular remodeling coupled with axonal outgrowth following cerebral ischemia is critical in improving poststroke neurological functional recovery. Antiangiogenic strategies can inhibit cancer vascularization and play a vital role in impeding cancer growth, invasion, and metastasis. Although there are significant differences in the cause of angiogenesis across both pathophysiological conditions, emerging evidence states that common signaling structures, such as extracellular vesicles (EVs) and noncoding RNAs (ncRNAs), are involved in this context. EVs, heterogeneous membrane vesicles encapsulating proteomic genetic information from parental cells, act as multifunctional regulators of intercellular communication. Among the multifaceted roles in modulating biological responses, exhaustive evidence shows that ncRNAs are selectively sorted into EVs, modulating common specific aspects of cancer development and stroke prognosis, namely, angiogenesis. This review will discuss recent advancements in the EV‐facilitated/inhibited progression of specific elements of angiogenesis with a particular concern about ncRNAs within these vesicles. The review is concluded by underlining the clinical opportunities of EV‐derived ncRNAs as diagnostic, prognostic, and therapeutic agents.

Extracellular Vesicle-Mediated Regulation Of Tumor Angiogenesis- Implications For Anti-Angiogenesis Therapy

Extracellular Vesicle‐mediated Regulation of Tumor Angiogenesis— Implications for Anti‐angiogenesis Therapy

New Insights into the Regulatory Roles of Extracellular Vesicles in Tumor Angiogenesis and Their Clinical Implications

Extracellular vesicles in tumor angiogenesis and resistance to anti-angiogenic therapy

Extracellular vesicles in the tumor microenvironment: Therapeutic resistance, clinical biomarkers, and targeting strategies

Tumor-Derived Extracellular Vesicles Regulate Cancer Progression in the Tumor Microenvironment

Noncoding RNAs of Extracellular Vesicles in Tumor Angiogenesis: From Biological Functions to Clinical Significance

Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospects

Role of Extracellular Vesicles in Tumour Microenvironment

Extracellular vesicles and the regulation of tumor immunity: Current progress and future directions

Tumor-derived Extracellular Vesicles: Regulators of Tumor Microenvironment and the Enlightenment in Tumor Therapy

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

The Biology and Function of Extracellular Vesicles in Cancer Development

Extracellular vesicles in breast cancer drug resistance and their clinical application

Extracellular Vesicles in Cancer Drug Resistance: Mechanistic Insights and Therapeutic Implications

Extracellular vesicles derived from immune cells: Role in tumor therapy

The Role of Tumor‐Derived Extracellular Vesicles in Drug Resistance in Urologic Cancers

Extracellular vesicles remodel tumor environment for cancer immunotherapy

Extracellular Vesicles as Delivery Shippers for Noncoding RNA‐Based Modulation of Angiogenesis: Insights from Ischemic Stroke and Cancer

Role of Extracellular Vesicles on Cancer Lymphangiogenesis and Lymph Node Metastasis

Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy